You are here

BİSFOSFONAT VE BİRLİKTE KULLANILAN SİSTEMİK İLAÇLARA BAĞLI OSTEONEKROZLAR

Osteonecrosis Due to Use of Bisphosphonates and Other Systemic Drugs

Journal Name:

Publication Year:

Keywords (Original Language):

Abstract (2. Language): 
Although bisphosphonates have been proven to cause osteonecrosis, most oncological patients’ medications are not limited to bisphosphonates. Dentists should be aware of the other drugs that these patients might use and their potential to raise the risk of osteonecrosis. The aim this paper is to emphasize the possible complications that oncologic drugs can cause during dental procedures.
Abstract (Original Language): 
Bisfosfonat kullanımının osteonekroza neden olabileceği literatürde belgelenmiş olsa da, çoğu onkolojik hastanın kullandığı ilaçlar bisfosfonatlarla sınırlı değildir. Diş hekimlerinin onkolojik hastaların kullanabileceği ve bisfosfonatların neden olduğu osteonekroz riskini arttırabilecek diğer ilaçlardan da haberdar olması gerekir. Bu makalenin amacı bu tür ilaçların onkolojik hastalarda dental girişimler sırasında komplikasyona yol açabilecek potansiyele sahip olduğunu vurgulamaktır.
60
65

REFERENCES

References: 

1. Almazrooa SA, Woo SB. Bisphosphonate
and nonbisphosphonate-associated osteonecrosis
of the jaw: a review. J Am Dent
Assoc, 2009 Jul; 140(7): 864-75.
2. American Association of Oral and
Maxillofacial Surgeons position paper on
bisphosphonate-related osteonecrosis of the
jaws. J Oral Maxillofac Surg, 2007 Mar;
65(3): 369-76.
3. Lam DK, Sándor GK, Holmes HI,
Evans AW, Clokie CM. A review of bisphosphonate-
associated osteonecrosis of the
jaws and its management. J Can Dent Assoc,
2007 Jun; 73(5): 417-22.
4. Pazianas M. Osteonecrosis of the jaw
and the role of macrophages. J Natl Cancer
Inst, 2011 Feb 2; 103(3): 232-40.
5. Dannemann C, Grätz KW, Riener MO,
Zwahlen RA. Jaw osteonecrosis related to
bisphosphonate therapy: a severe secondary
disorder. Bone, 2007 Apr; 40(4): 828-34.
6. Hoefert S, Eufinger H. Sunitinib may
raise the risk of bisphosphonate-related osteonecrosis
of the jaw: presentation of three
cases. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod, 2010 Oct; 110(4): 463-69.
7. Magopoulos C, Karakinaris G, Telioudis
Z, Vahtsevanos K, Dimitrakopoulos I,
Antoniadis K, Delaroudis S. Osteonecrosis
of the jaws due to bisphosphonate use: a review
of 60 cases and treatment proposals. Am
J Otolaryngol, 2007 May-Jun; 28(3): 158-63.
8. Migliorati CA, Covington JS 3rd. New
oncology drugs and osteonecrosis of the jaw
(ONJ). J Tenn Dent Assoc, 2009 Fall; 89(4):
36-38.
9. Migliorati CA. Bisphosphonates and
oral cavity avascular bone necrosis. J Clin
Oncol, 2003 Nov 15; 21(22): 4253-54.
10. Migliorati CA, Siegel MA, Elting LS.
Bisphosphonate-associated osteonecrosis: a
long term complication of bisphosphonate
treatment. Lancet Oncol, 2006 Jun; 7(6):
508-14.
11. Tanvetyanon T, Stiff PJ. Management
of adverse effects associated with intravenous
bisphosphonates. Ann Oncol, 2006;
17: 897-907.
12. Rutkowski JL. Combined use of
glucocorticoids and bisphosphonates may
increase severity of bisphosphonate-related
osteonecrosis of the jaw. J Oral Implantol,
2011 Oct; 37(5): 505.
13. Koch FP, Walter C, Hansen T, Jäger E,
Wagner W. Osteonecrosis of the jaw related
to sunitinib. Oral Maxillofac Surg, 2011 Mar;
15(1): 63-66.
14. Ayllon J, Launay-Vacher V, Medioni J,
Cros C, Spano JP, Oudard S. Osteonecrosis
of the jaw under bisphosphonate and antiangiogenic
therapies: cumulative toxicity profile?
Ann Oncol, 2009 Mar; 20(3): 600-601.
15. Bozas G, Roy A, Ramasamy V, Maraveyas
A. Osteonecrosis of the jaw after a
single bisphosphonate infusion in a patient
with metastatic renal cancer treated with
sunitinib. Onkologie, 2010; 33(6): 321-23.
16. Brunello A, Saia G, Bedogni A, Scaglione
D, Basso U. Worsening of osteonecrosis
of the jaw during treatment with sunitinib
in a patient with metastatic renal cell carcinoma.
Bone, 2009 Jan; 44(1): 173-75.
17. Christodoulou C, Pervena A, KlouM.
Tayşi, S. Şencan, S. Yıldırım
65
vas G, Galani E, Falagas ME, Tsakalos G,
Visvikis A, Nikolakopoulou A, Acholos V,
Karapanagiotidis G, Batziou E, Skarlos DV.
Combination of bisphosphonates and antiangiogenic
factors induces osteonecrosis of the
jaw more frequently than bisphosphonates
alone. Oncology, 2009; 76(3): 209-11.
18. Troeltzsch M, Woodlock T, Kriegelstein
S, Steiner T, Messlinger K, Troeltzsch
M. Physiology and pharmacology
of nonbisphosphonate drugs implicated in
osteonecrosis of the jaw. J Can Dent Assoc,
2012; 78: c85.
19. Fleissig Y, Regev E, Lehman H. Sunitinib
related osteonecrosis of jaw: a case
report. Oral Surg Oral Med Oral Pathol Oral
Radiol, 2012 Mar; 113(3): e1-3.
20. Agrillo A, Nastro Siniscalchi E, Facchini
A, Filiaci F, Ungari C. Osteonecrosis of
the jaws in patients assuming bisphosphonates
and sunitinib: two case reports. Eur Rev
Med Pharmacol Sci, 2012 Jul; 16(7): 952-57.
21. Nicolatou-Galitis O, Migkou M,
Psyrri A, Bamias A, Pectasides D, Economopoulos
T, Raber-Durlacher JE, Dimitriadis
G, Dimopoulos MA. Gingival bleeding and
jaw bone necrosis in patients with metastatic
renal cell carcinoma receiving sunitinib:
report of 2 cases with clinical implications.
Oral Surg Oral Med Oral Pathol Oral Radiol,
2012 Feb; 113(2): 234-38.

Thank you for copying data from http://www.arastirmax.com